Molecular Markers of Pancreatic Cancer: A 10-Year Retrospective Review of Molecular Advances
Pancreatic cancer remains the third leading cause of death amongst men and women in the United States. Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer maintains its reputation of being the most aggressive with a poor prognosis. One of the contributing factors to th...
Gespeichert in:
| Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2022-09, Vol.14 (9), p.e29485-e29485 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e29485 |
|---|---|
| container_issue | 9 |
| container_start_page | e29485 |
| container_title | Curēus (Palo Alto, CA) |
| container_volume | 14 |
| creator | Jacks, Boma E Ekpemiro, Chinwendum U Adeosun, Adeyemi A Ogbonna, Uchechukwu O Ogundiran, Faithful T Babalola, Funmilola Onyechi, Nkemputaife P Ajayi, Olamide O Boms, Maureen G Nwanguma, Adaugo N Udo, Uduak A Okobi, Okelue E Ohikhuai, Evidence E Evbayekha, Endurance O |
| description | Pancreatic cancer remains the third leading cause of death amongst men and women in the United States. Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer maintains its reputation of being the most aggressive with a poor prognosis. One of the contributing factors to the high mortality of PDAC is the absence of biomarkers for early detection of disease and the complexity of tumor biology and genomics. In this review, we explored the current understanding of epigenetics and diagnostic biomarkers in PDAC and summarized recent advances in molecular biology. We discussed current guidelines on diagnosis, prognosis, and treatment, especially in high-risk individuals. We also reviewed studies that have touched on identifying biomarkers and the role they play in making early diagnosis although there are currently no screening tools for PDAC. We explored the recent understanding of epigenetic alterations of PDAC and the future implications for early detection and prognosis. In conclusion, the new and emerging advances in the detection and treatment of PDAC can lead to an improvement in the current outcome of PDAC. |
| doi_str_mv | 10.7759/cureus.29485 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9588177</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2730495301</sourcerecordid><originalsourceid>FETCH-LOGICAL-c319t-21aaca22235467c6c32785a26585aced1eb856773036e58d17dd877635999e8b3</originalsourceid><addsrcrecordid>eNpdkV1LwzAUhoMoOObu_AEFb7ywMx9Nk3ohjOEXbCiiF4IQsvRMO7tmJm3Ff2-6Db9uknPI876ckxehQ4KHQvDs1DQOGj-kWSL5DupRkspYEpns_qr30cD7BcaYYEGxwD30PLUlmKbULppq9wbOR3Ye3enKONB1YaJxKMGdRaOI4PgJAncPtbN-BaYuWghdW8BHJ_pxGuVtp_IHaG-uSw-D7d1Hj5cXD-PreHJ7dTMeTWLDSFbHlGhtNKWU8SQVJjWMCsk1TXk4DeQEZpKnQjDMUuAyJyLPpRAp41mWgZyxPjrf-K6a2RJyA1XtdKlWrlhq96msLtTfl6p4VS-2VRmXkgTjPjreGjj73oCv1bLwBspSV2Abr6igGWeYyA49-ocubOOqsF6gGE7WXKBONpQJX-UdzL-HIVh1calNXGodF_sCXqSIzA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2730495301</pqid></control><display><type>article</type><title>Molecular Markers of Pancreatic Cancer: A 10-Year Retrospective Review of Molecular Advances</title><source>PubMed Central Free</source><source>PubMed Central Open Access</source><creator>Jacks, Boma E ; Ekpemiro, Chinwendum U ; Adeosun, Adeyemi A ; Ogbonna, Uchechukwu O ; Ogundiran, Faithful T ; Babalola, Funmilola ; Onyechi, Nkemputaife P ; Ajayi, Olamide O ; Boms, Maureen G ; Nwanguma, Adaugo N ; Udo, Uduak A ; Okobi, Okelue E ; Ohikhuai, Evidence E ; Evbayekha, Endurance O</creator><creatorcontrib>Jacks, Boma E ; Ekpemiro, Chinwendum U ; Adeosun, Adeyemi A ; Ogbonna, Uchechukwu O ; Ogundiran, Faithful T ; Babalola, Funmilola ; Onyechi, Nkemputaife P ; Ajayi, Olamide O ; Boms, Maureen G ; Nwanguma, Adaugo N ; Udo, Uduak A ; Okobi, Okelue E ; Ohikhuai, Evidence E ; Evbayekha, Endurance O</creatorcontrib><description>Pancreatic cancer remains the third leading cause of death amongst men and women in the United States. Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer maintains its reputation of being the most aggressive with a poor prognosis. One of the contributing factors to the high mortality of PDAC is the absence of biomarkers for early detection of disease and the complexity of tumor biology and genomics. In this review, we explored the current understanding of epigenetics and diagnostic biomarkers in PDAC and summarized recent advances in molecular biology. We discussed current guidelines on diagnosis, prognosis, and treatment, especially in high-risk individuals. We also reviewed studies that have touched on identifying biomarkers and the role they play in making early diagnosis although there are currently no screening tools for PDAC. We explored the recent understanding of epigenetic alterations of PDAC and the future implications for early detection and prognosis. In conclusion, the new and emerging advances in the detection and treatment of PDAC can lead to an improvement in the current outcome of PDAC.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.29485</identifier><language>eng</language><publisher>Palo Alto: Cureus Inc</publisher><subject>Asymptomatic ; Biomarkers ; Clinical trials ; DNA methylation ; Endoscopy ; Epigenetics ; Gastroenterology ; Gene expression ; Genomes ; Genomics ; Internal Medicine ; Kinases ; Medical diagnosis ; Medical prognosis ; Mortality ; Mutation ; Oncology ; Pancreatic cancer</subject><ispartof>Curēus (Palo Alto, CA), 2022-09, Vol.14 (9), p.e29485-e29485</ispartof><rights>Copyright © 2022, Jacks et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2022, Jacks et al. 2022 Jacks et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c319t-21aaca22235467c6c32785a26585aced1eb856773036e58d17dd877635999e8b3</citedby><cites>FETCH-LOGICAL-c319t-21aaca22235467c6c32785a26585aced1eb856773036e58d17dd877635999e8b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588177/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588177/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Jacks, Boma E</creatorcontrib><creatorcontrib>Ekpemiro, Chinwendum U</creatorcontrib><creatorcontrib>Adeosun, Adeyemi A</creatorcontrib><creatorcontrib>Ogbonna, Uchechukwu O</creatorcontrib><creatorcontrib>Ogundiran, Faithful T</creatorcontrib><creatorcontrib>Babalola, Funmilola</creatorcontrib><creatorcontrib>Onyechi, Nkemputaife P</creatorcontrib><creatorcontrib>Ajayi, Olamide O</creatorcontrib><creatorcontrib>Boms, Maureen G</creatorcontrib><creatorcontrib>Nwanguma, Adaugo N</creatorcontrib><creatorcontrib>Udo, Uduak A</creatorcontrib><creatorcontrib>Okobi, Okelue E</creatorcontrib><creatorcontrib>Ohikhuai, Evidence E</creatorcontrib><creatorcontrib>Evbayekha, Endurance O</creatorcontrib><title>Molecular Markers of Pancreatic Cancer: A 10-Year Retrospective Review of Molecular Advances</title><title>Curēus (Palo Alto, CA)</title><description>Pancreatic cancer remains the third leading cause of death amongst men and women in the United States. Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer maintains its reputation of being the most aggressive with a poor prognosis. One of the contributing factors to the high mortality of PDAC is the absence of biomarkers for early detection of disease and the complexity of tumor biology and genomics. In this review, we explored the current understanding of epigenetics and diagnostic biomarkers in PDAC and summarized recent advances in molecular biology. We discussed current guidelines on diagnosis, prognosis, and treatment, especially in high-risk individuals. We also reviewed studies that have touched on identifying biomarkers and the role they play in making early diagnosis although there are currently no screening tools for PDAC. We explored the recent understanding of epigenetic alterations of PDAC and the future implications for early detection and prognosis. In conclusion, the new and emerging advances in the detection and treatment of PDAC can lead to an improvement in the current outcome of PDAC.</description><subject>Asymptomatic</subject><subject>Biomarkers</subject><subject>Clinical trials</subject><subject>DNA methylation</subject><subject>Endoscopy</subject><subject>Epigenetics</subject><subject>Gastroenterology</subject><subject>Gene expression</subject><subject>Genomes</subject><subject>Genomics</subject><subject>Internal Medicine</subject><subject>Kinases</subject><subject>Medical diagnosis</subject><subject>Medical prognosis</subject><subject>Mortality</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Pancreatic cancer</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkV1LwzAUhoMoOObu_AEFb7ywMx9Nk3ohjOEXbCiiF4IQsvRMO7tmJm3Ff2-6Db9uknPI876ckxehQ4KHQvDs1DQOGj-kWSL5DupRkspYEpns_qr30cD7BcaYYEGxwD30PLUlmKbULppq9wbOR3Ye3enKONB1YaJxKMGdRaOI4PgJAncPtbN-BaYuWghdW8BHJ_pxGuVtp_IHaG-uSw-D7d1Hj5cXD-PreHJ7dTMeTWLDSFbHlGhtNKWU8SQVJjWMCsk1TXk4DeQEZpKnQjDMUuAyJyLPpRAp41mWgZyxPjrf-K6a2RJyA1XtdKlWrlhq96msLtTfl6p4VS-2VRmXkgTjPjreGjj73oCv1bLwBspSV2Abr6igGWeYyA49-ocubOOqsF6gGE7WXKBONpQJX-UdzL-HIVh1calNXGodF_sCXqSIzA</recordid><startdate>20220923</startdate><enddate>20220923</enddate><creator>Jacks, Boma E</creator><creator>Ekpemiro, Chinwendum U</creator><creator>Adeosun, Adeyemi A</creator><creator>Ogbonna, Uchechukwu O</creator><creator>Ogundiran, Faithful T</creator><creator>Babalola, Funmilola</creator><creator>Onyechi, Nkemputaife P</creator><creator>Ajayi, Olamide O</creator><creator>Boms, Maureen G</creator><creator>Nwanguma, Adaugo N</creator><creator>Udo, Uduak A</creator><creator>Okobi, Okelue E</creator><creator>Ohikhuai, Evidence E</creator><creator>Evbayekha, Endurance O</creator><general>Cureus Inc</general><general>Cureus</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220923</creationdate><title>Molecular Markers of Pancreatic Cancer: A 10-Year Retrospective Review of Molecular Advances</title><author>Jacks, Boma E ; Ekpemiro, Chinwendum U ; Adeosun, Adeyemi A ; Ogbonna, Uchechukwu O ; Ogundiran, Faithful T ; Babalola, Funmilola ; Onyechi, Nkemputaife P ; Ajayi, Olamide O ; Boms, Maureen G ; Nwanguma, Adaugo N ; Udo, Uduak A ; Okobi, Okelue E ; Ohikhuai, Evidence E ; Evbayekha, Endurance O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c319t-21aaca22235467c6c32785a26585aced1eb856773036e58d17dd877635999e8b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Asymptomatic</topic><topic>Biomarkers</topic><topic>Clinical trials</topic><topic>DNA methylation</topic><topic>Endoscopy</topic><topic>Epigenetics</topic><topic>Gastroenterology</topic><topic>Gene expression</topic><topic>Genomes</topic><topic>Genomics</topic><topic>Internal Medicine</topic><topic>Kinases</topic><topic>Medical diagnosis</topic><topic>Medical prognosis</topic><topic>Mortality</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Pancreatic cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jacks, Boma E</creatorcontrib><creatorcontrib>Ekpemiro, Chinwendum U</creatorcontrib><creatorcontrib>Adeosun, Adeyemi A</creatorcontrib><creatorcontrib>Ogbonna, Uchechukwu O</creatorcontrib><creatorcontrib>Ogundiran, Faithful T</creatorcontrib><creatorcontrib>Babalola, Funmilola</creatorcontrib><creatorcontrib>Onyechi, Nkemputaife P</creatorcontrib><creatorcontrib>Ajayi, Olamide O</creatorcontrib><creatorcontrib>Boms, Maureen G</creatorcontrib><creatorcontrib>Nwanguma, Adaugo N</creatorcontrib><creatorcontrib>Udo, Uduak A</creatorcontrib><creatorcontrib>Okobi, Okelue E</creatorcontrib><creatorcontrib>Ohikhuai, Evidence E</creatorcontrib><creatorcontrib>Evbayekha, Endurance O</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jacks, Boma E</au><au>Ekpemiro, Chinwendum U</au><au>Adeosun, Adeyemi A</au><au>Ogbonna, Uchechukwu O</au><au>Ogundiran, Faithful T</au><au>Babalola, Funmilola</au><au>Onyechi, Nkemputaife P</au><au>Ajayi, Olamide O</au><au>Boms, Maureen G</au><au>Nwanguma, Adaugo N</au><au>Udo, Uduak A</au><au>Okobi, Okelue E</au><au>Ohikhuai, Evidence E</au><au>Evbayekha, Endurance O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular Markers of Pancreatic Cancer: A 10-Year Retrospective Review of Molecular Advances</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><date>2022-09-23</date><risdate>2022</risdate><volume>14</volume><issue>9</issue><spage>e29485</spage><epage>e29485</epage><pages>e29485-e29485</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Pancreatic cancer remains the third leading cause of death amongst men and women in the United States. Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer maintains its reputation of being the most aggressive with a poor prognosis. One of the contributing factors to the high mortality of PDAC is the absence of biomarkers for early detection of disease and the complexity of tumor biology and genomics. In this review, we explored the current understanding of epigenetics and diagnostic biomarkers in PDAC and summarized recent advances in molecular biology. We discussed current guidelines on diagnosis, prognosis, and treatment, especially in high-risk individuals. We also reviewed studies that have touched on identifying biomarkers and the role they play in making early diagnosis although there are currently no screening tools for PDAC. We explored the recent understanding of epigenetic alterations of PDAC and the future implications for early detection and prognosis. In conclusion, the new and emerging advances in the detection and treatment of PDAC can lead to an improvement in the current outcome of PDAC.</abstract><cop>Palo Alto</cop><pub>Cureus Inc</pub><doi>10.7759/cureus.29485</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-8184 |
| ispartof | Curēus (Palo Alto, CA), 2022-09, Vol.14 (9), p.e29485-e29485 |
| issn | 2168-8184 2168-8184 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9588177 |
| source | PubMed Central Free; PubMed Central Open Access |
| subjects | Asymptomatic Biomarkers Clinical trials DNA methylation Endoscopy Epigenetics Gastroenterology Gene expression Genomes Genomics Internal Medicine Kinases Medical diagnosis Medical prognosis Mortality Mutation Oncology Pancreatic cancer |
| title | Molecular Markers of Pancreatic Cancer: A 10-Year Retrospective Review of Molecular Advances |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T00%3A07%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20Markers%20of%20Pancreatic%20Cancer:%20A%2010-Year%20Retrospective%20Review%20of%20Molecular%20Advances&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Jacks,%20Boma%20E&rft.date=2022-09-23&rft.volume=14&rft.issue=9&rft.spage=e29485&rft.epage=e29485&rft.pages=e29485-e29485&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.29485&rft_dat=%3Cproquest_pubme%3E2730495301%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2730495301&rft_id=info:pmid/&rfr_iscdi=true |